FONT-SIZE Plus   Neg

Biolase Technology Slips To Loss In Q4

Biolase Technology, Inc. (BLTI) reported Thursday a fourth-quarter net loss of $2.0 million or $0.06 per share, compared to net income of $174,000 or $0.01 per share last year.

Excluding iems, non-GAAP net loss was $1.3 million or $0.04 per share, compared to non-GAAP net income of $0.9 million or $0.04 per share.

On average, 5 analysts polled by Thomson Reuters expected the company to report a loss of $0.02 per share for the quarter. Analysts' estimates typically exclude one-time items.

Net revenue for the quarter rose 36 percent to $13.2 million from $9.7 million last year, primarily driven by Biolase's exit from an exclusive distribution arrangement in August 2010 with Henry Schein,Inc.(HSIC) and the company's return to a direct sales and selected-distributor business model. Analysts expected revenues of $13.10 million.

Looking forward, the company expects revenue of approximately $11 million for the first quarter of fiscal 2012, Analysts expect first quarter revenue of $13.23 million. For the full year 2012, the company expects revenue of $57 million-$60 million . Analysts expect revenue of $66.31 million for the full year 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

Editors Pick
Apple confirmed that it has bought face animation software firm Faceshift, although it was tight lipped about how it intends to use the new addition. The move is speculated as a bid to expand into virtual reality. Environment ministry of South Korea Thursday ordered Volkswagen Korea to recall 125,522 diesel vehicles on determining actual emissions of nitrogen oxides. The ministry has asked the German automobile maker to pay a fine of 14.1 billion Won or $12.31 million. The company has to submit a recall plan by January 6, 2016. The U.S. Food and Drug Administration has alerted health care professionals and patients of a voluntary recall of compounded multivitamin capsules containing high amounts of Vitamin D3 (Cholecalciferol), distributed nationwide by Glades Drugs in Pahokee, Florida. FDA has received reports of several...
comments powered by Disqus
Follow RTT